ALIM Alimera Sciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ALIM

Price (delayed)

$5.58

Market cap

$292.33M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.23

Enterprise value

$347.64M

Alimera Sciences is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or ...

Highlights
Alimera Sciences's gross profit has soared by 64% YoY and by 12% from the previous quarter
The revenue has surged by 62% year-on-year and by 12% since the previous quarter
The EPS has grown by 50% YoY but it has contracted by 46% from the previous quarter
ALIM's debt has surged by 57% year-on-year and by 8% since the previous quarter
Alimera Sciences's net income has decreased by 25% YoY and by 6% QoQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.alimerasciences.com
Peers: INSM REGN ALDX TTOO

Key stats

What are the main financial stats of ALIM
Market
Shares outstanding
52.39M
Market cap
$292.33M
Enterprise value
$347.64M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
7.19
Price to sales (P/S)
3.36
EV/EBIT
N/A
EV/EBITDA
169.91
EV/Sales
3.85
Earnings
Revenue
$90.22M
EBIT
-$9.11M
EBITDA
$2.05M
Free cash flow
-$12.89M
Per share
EPS
-$1.23
Free cash flow per share
-$0.24
Book value per share
$0.78
Revenue per share
$1.66
TBVPS
$1.07
Balance sheet
Total assets
$152.49M
Total liabilities
$111.83M
Debt
$69.66M
Equity
$40.65M
Working capital
$33.68M
Liquidity
Debt to equity
1.71
Current ratio
2.62
Quick ratio
2.34
Net debt/EBITDA
27.03
Margins
EBITDA margin
2.3%
Gross margin
86.5%
Net margin
-23.7%
Operating margin
-1%
Efficiency
Return on assets
-14.7%
Return on equity
-49.8%
Return on invested capital
-10.4%
Return on capital employed
-6.9%
Return on sales
-10.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALIM stock price

How has the Alimera Sciences stock price performed over time
Intraday
-0.18%
1 week
0.18%
1 month
1.09%
1 year
68.07%
YTD
29.17%
QTD
0.36%

Financial performance

How have Alimera Sciences's revenue and profit performed over time
Revenue
$90.22M
Gross profit
$78.06M
Operating income
-$932,000
Net income
-$21.42M
Gross margin
86.5%
Net margin
-23.7%
ALIM's operating margin has soared by 95% YoY and by 58% QoQ
The operating income has soared by 91% year-on-year and by 52% since the previous quarter
Alimera Sciences's gross profit has soared by 64% YoY and by 12% from the previous quarter
The revenue has surged by 62% year-on-year and by 12% since the previous quarter

Growth

What is Alimera Sciences's growth rate over time

Valuation

What is Alimera Sciences stock price valuation
P/E
N/A
P/B
7.19
P/S
3.36
EV/EBIT
N/A
EV/EBITDA
169.91
EV/Sales
3.85
The EPS has grown by 50% YoY but it has contracted by 46% from the previous quarter
ALIM's price to book (P/B) is 167% higher than its last 4 quarters average of 2.7
The equity is down by 12% since the previous quarter
The stock's P/S is 141% more than its last 4 quarters average of 1.4
The revenue has surged by 62% year-on-year and by 12% since the previous quarter

Efficiency

How efficient is Alimera Sciences business performance
Alimera Sciences's return on assets has surged by 61% YoY and by 12% QoQ
ALIM's ROIC has soared by 58% YoY and by 17% from the previous quarter
The ROS has grown by 48% YoY and by 17% from the previous quarter
ALIM's ROE is up by 29% QoQ

Dividends

What is ALIM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALIM.

Financial health

How did Alimera Sciences financials performed over time
Alimera Sciences's total assets is 36% more than its total liabilities
ALIM's total liabilities has soared by 67% YoY and by 4.2% QoQ
Alimera Sciences's quick ratio has increased by 10% QoQ and by 4.9% YoY
ALIM's debt is 71% greater than its equity
The debt to equity has soared by 173% YoY and by 22% from the previous quarter
ALIM's debt has surged by 57% year-on-year and by 8% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.